CN117751114A - 葡糖脑苷脂酶活性的小分子调节剂及其用途 - Google Patents

葡糖脑苷脂酶活性的小分子调节剂及其用途 Download PDF

Info

Publication number
CN117751114A
CN117751114A CN202280046279.XA CN202280046279A CN117751114A CN 117751114 A CN117751114 A CN 117751114A CN 202280046279 A CN202280046279 A CN 202280046279A CN 117751114 A CN117751114 A CN 117751114A
Authority
CN
China
Prior art keywords
substituted
compound
pharmaceutically acceptable
acceptable salt
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280046279.XA
Other languages
English (en)
Chinese (zh)
Inventor
K·亨特
郑剑斌
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fanfang Biochemical Co
Original Assignee
Fanfang Biochemical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fanfang Biochemical Co filed Critical Fanfang Biochemical Co
Publication of CN117751114A publication Critical patent/CN117751114A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202280046279.XA 2021-04-30 2022-04-28 葡糖脑苷脂酶活性的小分子调节剂及其用途 Pending CN117751114A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163182734P 2021-04-30 2021-04-30
US63/182,734 2021-04-30
PCT/US2022/026676 WO2022232360A1 (en) 2021-04-30 2022-04-28 Small molecule modulators of glucocerebrosidase activity and uses thereof

Publications (1)

Publication Number Publication Date
CN117751114A true CN117751114A (zh) 2024-03-22

Family

ID=83848814

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280046279.XA Pending CN117751114A (zh) 2021-04-30 2022-04-28 葡糖脑苷脂酶活性的小分子调节剂及其用途

Country Status (10)

Country Link
US (1) US20240246952A1 (https=)
EP (1) EP4329880A4 (https=)
JP (1) JP2024517789A (https=)
KR (1) KR20240016286A (https=)
CN (1) CN117751114A (https=)
AU (1) AU2022267285A1 (https=)
BR (1) BR112023022567A2 (https=)
CA (1) CA3218510A1 (https=)
MX (1) MX2023012853A (https=)
WO (1) WO2022232360A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025237303A1 (zh) * 2024-05-14 2025-11-20 先声药业有限公司 β-葡萄糖脑苷脂酶变构调节剂、其药物组合物及用途

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1898206A (zh) * 2003-11-06 2007-01-17 艾德斯制药股份有限公司 代谢型谷氨酸受体的别构调节剂
WO2010045303A2 (en) * 2008-10-16 2010-04-22 Schering Corporation Pyrrolidine, piperidine and piperazine derivatives and methods of use thereof
WO2011025690A1 (en) * 2009-08-27 2011-03-03 Merck Sharp & Dohme Corp. Novel pyrrolidine derived beta 3 adrenergic receptor agonists
CN102655747A (zh) * 2009-10-19 2012-09-05 阿米库斯治疗学公司 用于预防和/或治疗中枢神经系统退行性失调的新颖组合物
WO2015095963A1 (en) * 2013-12-23 2015-07-02 Alectos Therapeutics Inc. Glucocerebrosidase modulators and uses thereof
CN105338812A (zh) * 2013-03-15 2016-02-17 怀特黑德生物医学研究院 苯并咪唑衍生物及其用途
CN108290855A (zh) * 2015-07-01 2018-07-17 西北大学 被取代的喹唑啉化合物及其调节葡糖脑苷脂酶活性的用途
CN111386259A (zh) * 2017-08-02 2020-07-07 西北大学 经取代稠合的嘧啶化合物及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7488721B2 (en) * 2004-05-13 2009-02-10 Mcmaster University Real time methylumbelliferone-based assay
EP4039685A1 (en) * 2021-02-08 2022-08-10 Irbm S.P.A. Azabicyclic shp2 inhibitors

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1898206A (zh) * 2003-11-06 2007-01-17 艾德斯制药股份有限公司 代谢型谷氨酸受体的别构调节剂
WO2010045303A2 (en) * 2008-10-16 2010-04-22 Schering Corporation Pyrrolidine, piperidine and piperazine derivatives and methods of use thereof
WO2011025690A1 (en) * 2009-08-27 2011-03-03 Merck Sharp & Dohme Corp. Novel pyrrolidine derived beta 3 adrenergic receptor agonists
CN102655747A (zh) * 2009-10-19 2012-09-05 阿米库斯治疗学公司 用于预防和/或治疗中枢神经系统退行性失调的新颖组合物
CN105367485A (zh) * 2009-10-19 2016-03-02 阿米库斯治疗学公司 用于预防和/或治疗中枢神经系统退行性失调的新颖组合物
CN105338812A (zh) * 2013-03-15 2016-02-17 怀特黑德生物医学研究院 苯并咪唑衍生物及其用途
WO2015095963A1 (en) * 2013-12-23 2015-07-02 Alectos Therapeutics Inc. Glucocerebrosidase modulators and uses thereof
CN108290855A (zh) * 2015-07-01 2018-07-17 西北大学 被取代的喹唑啉化合物及其调节葡糖脑苷脂酶活性的用途
CN111386259A (zh) * 2017-08-02 2020-07-07 西北大学 经取代稠合的嘧啶化合物及其用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
COLUMBUS, OHIO, US: "REGISTRY[online]", 《STN检索报告 US REGISTRY》, 10 June 2019 (2019-06-10), pages 1 *
HUANG, WW ET AL.: "N4-Phenyl modifications of N2-(2-hydroxyl)ethyl-6-(pyrrolidin-1-yl)-1, 3, 5-triazine-2, 4-diamines enhance glucocerebrosidase inhibition by small molecules with potential as chemical chaperones for Gaucher disease", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 17, no. 21, 28 August 2007 (2007-08-28), pages 5783 - 5789 *
MARUGAN, JJ ET AL.: "Evaluation of Quinazoline Analogues as Glucocerebrosidase Inhibitors with Chaperone Activity", JOURNAL OF MEDICINAL CHEMISTRY, vol. 54, no. 4, 20 January 2011 (2011-01-20), pages 1033 - 1058 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025237303A1 (zh) * 2024-05-14 2025-11-20 先声药业有限公司 β-葡萄糖脑苷脂酶变构调节剂、其药物组合物及用途

Also Published As

Publication number Publication date
WO2022232360A1 (en) 2022-11-03
MX2023012853A (es) 2024-01-12
US20240246952A1 (en) 2024-07-25
EP4329880A1 (en) 2024-03-06
BR112023022567A2 (pt) 2024-02-06
AU2022267285A1 (en) 2023-11-09
KR20240016286A (ko) 2024-02-06
CA3218510A1 (en) 2022-11-03
JP2024517789A (ja) 2024-04-23
EP4329880A4 (en) 2025-03-05

Similar Documents

Publication Publication Date Title
CN114671864B (zh) 杂芳基取代的吡啶及使用方法
JP7427812B2 (ja) 血漿カリクレインの阻害剤およびその使用
US9388173B2 (en) PRMT5 inhibitors and uses thereof
HK1224140A1 (zh) 转录因子抑制剂及其用途
CN105073768A (zh) Ras抑制剂及其用途
JP2016505002A (ja) ジヒドロイソキノリンまたはテトラヒドロイソキノリンを含有するｐｒｍｔ５阻害剤およびその使用
CN117642404A (zh) 葡糖脑苷脂酶活性的小分子调节剂及其用途
JP2024529487A (ja) Ｒｏｃｋ２阻害剤およびその使用
CN119212707A (zh) 噁二唑hdac6抑制剂及其用途
US20240109898A1 (en) Substituted pyrazolo[1,5-a]pyrimidine-7-amine derivatives, compositions and pharmaceutical uses thereof
CN117751114A (zh) 葡糖脑苷脂酶活性的小分子调节剂及其用途
US20260070917A1 (en) Cyclin dependent kinase degraders and methods of use thereof
JP2024539628A (ja) グルコセレブロシダーゼ活性の小分子モジュレーターおよびその使用
CN118055926A (zh) Rock2抑制剂及其用途
WO2025151449A1 (en) Bifunctional p53-binding compounds and uses thereof
HK40123072A (en) Inhibitors of plasma kallikrein and uses thereof
TW202543631A (zh) 嗒嗪酮ｃ５ａｒ１拮抗劑及其用途
HK40029252B (en) Inhibitors of plasma kallikrein and uses thereof
HK40029252A (en) Inhibitors of plasma kallikrein and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination